MIT class project turns into an FDA-cleared treatment for tremors
An MIT class project has culminated in Encora Therapeutics receiving FDA clearance for a wrist-worn device that significantly reduces essential tremors. This inspiring journey from a student prototype to a commercial medical device showcases the power of academic innovation and perseverance. Hacker News often champions such deep dives into engineering challenges with tangible, life-changing results.
The Lowdown
Encora Therapeutics has achieved a remarkable milestone, securing FDA clearance for a novel wrist device designed to alleviate essential tremors. What began as a speculative idea in a 2017 MIT product design class, and almost didn't make the cut, has transformed into a life-changing technology, demonstrating the profound impact of student ingenuity and sustained entrepreneurial drive.
- Dramatic Debut: The device first gained notoriety during an MIT class presentation where a Parkinson's patient, Michael, dramatically reduced his tremors live on stage, moving the audience to a standing ovation.
- From Concept to Company: Despite initial skepticism from its inventor, the prototype sparked intense interest, leading the student team to leverage MIT's entrepreneurial resources and officially form Encora Therapeutics in 2020.
- Rigorous Development: The path involved numerous hardware iterations, extensive clinical trials, and a pivot from Parkinson's to essential tremor, identifying it as a greater unmet need.
- Mechanism of Action: The device uses mechanical vibrations on the wrist to send patterned signals to stretch receptors, which then travel through the nervous system to the same brain regions targeted by invasive tremor surgeries.
- Proven Efficacy: Clinical trials demonstrated significant improvement in over 70% of patients, leading to the FDA's 510(k) clearance in February 2024.
Now, Encora Therapeutics is focused on commercializing the device, building a sales force, and securing insurance coverage to make this 'life-changing' technology widely available. Looking ahead, the company aims to address Parkinson's tremors and explore the broader potential of wearable neuromodulation as a platform technology for various neurological conditions.